Knockdown of BCL6 Inhibited Malignant Phenotype and Enhanced Sensitivity of Glioblastoma Cells to TMZ through AKT Pathway

Figure 5

Reduction of BCL6 increases chemosensitivity of Glioma Cells to Temozolomide. (a) The cells transfected with scrambled shRNA or shBCL6 were treated with TMZ at different concentrations, and cell survival was measured by CCK8 assay. Data were normalized to the Scrambled group with 0 μM TMZ. (b) The cell viability was assayed by CCK8 at 0, 24, 48, and 72 h after TMZ (150μM). Data were normalized to the Scrambled group at 0 hours. (c) The apoptosis rate of U87 and U251 with different treatment was measured by flow cytometry assay ( p<0.01; p<0.05; p<0.01; p<0.05).

(a)

(b)

(c)